BOSTON – Cutting-edge techniques for the diagnosis of prostate cancer will be the focus of what’s being called a global summit this weekend in Boston. Experts are expected to discuss new and emerging prostate diagnostics at the conference. It’s sponsored by the Boston-based nonprofit AdMeTech Foundation. Organizers say the summit will focus on breakthroughs that…
Boston Business Journal Article Sep 16, 2016 AdMeTech Foundation says it can save Massachusetts more than $200 million annually by using MRIs to diagnose aggressive prostate cancer. The finding is based on a clinical trial conducted at Brigham and Women’s Hospital in partnership with AdMeTech, a Boston-based non-profit to advance diagnosis and treatment of…
Media Contact: Kate Lagreca kate@northwindstrategies.com Clinical Trial Shows that MRI May Have Groundbreaking Impact on Prostate Cancer Care AdMeTech Foundation to Unveil Clinical Trial Results at First Global Summit on Precision Diagnosis for Prostate Cancer BOSTON, MA—September 16, 2015—AdMeTech Foundation will unveil the results of a clinical MRI trial at the First Global Summit on…
FOR IMMEDIATE RELEASE Media Contact: Kate Lagreca kate@northwindstrategies.com AdMeTech Marks Prostate Cancer Awareness Month with Community Events Across Massachusetts BOSTON, MA—September 9, 2015—AdMeTech Foundation, a Boston non-profit focused on prostate cancer research and awareness, will observe September as National Prostate Cancer Awareness Month with five educational events throughout the state. AdMeTech’s mission…
August 2, 2016 Vincent J. Gnanapragasam [ultimate_spacer height=”32″] Abstract Introduction Over 80% of the nearly 1 million men diagnosed with prostate cancer annually worldwide present with localised or locally advanced non-metastatic disease. Risk stratification is the cornerstone for clinical decision making and treatment selection for these men. The most widely applied stratification systems use presenting…
Women of Influence: AdMeTech Foundation Chief Faina Shtern takes on prostate cancer. After she emigrated from the Soviet Union as a Jewish refugee escaping oppression, Faina Shtern knew what she wanted to do once she landed in America in the late 1970s: medical research.
With a medical degree from Chemovets Medical School in the Ukraine, Shtern proceeded to pursue her dream, eventually working at a number of prestigious institutions over the years, including being appointed a clinical and research fellow at Massachusetts General Hospital and Harvard Medical School, where she subsequently became a faculty member.
PUBLIC RELEASE: 28-JUL-2016 Full Article Prostate cancer patients have been offered hope after scientists at Newcastle University, UK, have identified a new group of molecules that could be targeted to slow tumor growth. Experts used an advanced screening technique which found hundreds of genes were affected by the male hormone testosterone. It is believed this could…
PUBLIC RELEASE: 28-JUL-2016 [ultimate_spacer height=”32″]Full Article[ultimate_spacer height=”32″] Study reveals protein’s ability to block expression of metastasis-linked genes UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER PUBLIC RELEASE: 28-JUL-2016 Although it reads like European license plate number, a protein known as ZMYND8 has demonstrated its ability to block metastasis-linked genes in prostate cancer, according to a study at…
New York, NY, July 25, 2016 Researchers found no significant differences in health related quality of life between patients with low risk prostate cancer on active surveillance and men without the disease over 3 years of followup, according to new study in the Journal of Urology ELSEVIER HEALTH SCIENCES [ultimate_spacer height=”32″]Full Article[ultimate_spacer height=”32″] Active surveillance…
New York, NY, July 27, 2016 [ultimate_spacer height=”32″]Full Article[ultimate_spacer height=”32″] Assessment of clinical and nonclinical factors indicates that black men on active surveillance are more likely to pursue active treatment, according to a new study published in The Journal of Urology® ELSEVIER HEALTH SCIENCES Although active surveillance, or watchful waiting, for patients with low risk…